Ginolis
Specialising in automated diagnostics and liquid-handling robotics, Ginolis was acquired by Cellink, a bioprinting technology developer, in early 2021. The acquisition enabled Cellink to deliver large-scale automation projects to customers in the healthtech and diagnostics sectors.
Exit type
Acquisition, 2/2021
Purchase price
€70 million
Investment multiple at exit
0.93x
Investment’s IRR
-2.5%
Returns for Springvest
€0.25 million (before taxes)
Springvest’s funding rounds
9/2016
Total funding arranged by Springvest
€2.15 million
